Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Jessica M. Frakes

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1901-0933; OpenAlex author ID A5023129507, A5139606642. Sources: OpenAlex.

Their work

Papers
24 (first author 4, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
109
Papers, trials and grants by year

2015: 4 papers · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 2 papers · 2023: 3 papers · 2024: 1 paper · 2025: 3 papers · 2026: 2 papers

Papers 24

  1. Radiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline. Co-author DOI 10.1016/j.prro.2026.07.002↗
  2. Dynamic tumor tracking for locally advanced pancreatic cancer: precision in motion. Last author DOI 10.21037/tcr-2026-0588↗
  3. To irradiate or electroporate: how should we ablate pancreatic cancer? Co-author DOI 10.21037/tgh-24-164↗
  4. Association of Pathologic Response and Adjuvant Chemotherapy with Survival in Resected Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy. Co-author DOI 10.3390/cancers17111797↗
  5. Personalizing Patient Education for Pancreatic Cancer Patients Receiving Multidisciplinary Care with Integration of Novel Digital Tools. Co-author DOI 10.3390/healthcare13151929↗
  6. The Evolving Role of Neoadjuvant Radiation Therapy in Pancreatic Adenocarcinoma. Last author DOI 10.3390/jcm13226800↗
  7. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-control… First author DOI 10.1016/s1470-2045(23)00478-3↗
  8. Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic R… Co-author DOI 10.1177/10732748221150228↗
  9. Ablative 5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy for Oligometastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1177/10732748231219069↗
  10. Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient Selection. Co-author DOI 10.1007/s11605-021-05130-x↗
  11. Surgical and Pathologic Outcomes of Pancreatic Adenocarcinoma (PA) After Preoperative Ablative Stereotactic Magnetic Resonance Image Guided Adaptive Radiation … Last author DOI 10.1016/j.adro.2022.101045↗
  12. Delta radiomics analysis of Magnetic Resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer. Co-author DOI 10.1186/s13014-021-01957-5↗
  13. Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic… First author DOI 10.1016/j.ijrobp.2020.09.022↗
  14. Transarterial Radioembolization Treatment of Pancreatic Cancer Patients with Liver-Dominant Metastatic Disease Using Yttrium-90 Glass Microspheres: A Single-In… Co-author DOI 10.1016/j.jvir.2019.11.037↗
  15. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  16. Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy. Co-author DOI 10.21037/jgo.2017.09.13↗
  17. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy… Co-author DOI 10.1080/0284186x.2016.1256497↗
  18. Outcomes of adjuvant radiotherapy and lymph node resection in elderly patients with pancreatic cancer treated with surgery and chemotherapy. Co-author DOI 10.21037/jgo.2017.08.05↗
  19. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy co… Co-author DOI 10.21037/jgo.2016.03.15↗
  20. Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer. First author DOI 10.3978/j.issn.2078-6891.2015.075↗
  21. Resected pancreatic cancer outcomes in the elderly. Co-author DOI 10.1016/j.jgo.2014.11.005↗
  22. Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer. Co-author DOI 10.1016/j.radonc.2015.07.018↗
  23. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarc… Co-author DOI 10.3109/0284186x.2015.1004367↗
  24. Management of borderline resectable pancreatic cancer. First author DOI 10.4251/wjgo.v7.i10.241↗

Closest collaborators

The 25 strongest of 109 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sarah E. Hoffe · 21 shared papers, 2015–2026 · strength 2.86
  2. Mokenge Peter Malafa · 15 shared papers, 2015–2025 · strength 1.76
  3. Pamela Joy Hodul · 12 shared papers, 2015–2025 · strength 1.36
  4. Jason W. Denbo · 5 shared papers, 2022–2025 · strength 0.85
  5. John Michael Bryant · 4 shared papers, 2022–2025 · strength 0.81
  6. Russell F. Palm · 5 shared papers, 2021–2025 · strength 0.79
  7. Michael David Chuong · 6 shared papers, 2015–2026 · strength 0.70
  8. Jason B. Fleming · 4 shared papers, 2022–2025 · strength 0.63
  9. Eric A. Mellon · 7 shared papers, 2015–2019 · strength 0.44
  10. Jason Gurewitz · 1 shared paper, 2026 · strength 0.43
  11. Jennifer B. Permuth · 1 shared paper, 2026 · strength 0.43
  12. Joseph M. Herman · 3 shared papers, 2020–2025 · strength 0.42
  13. Nicole Nardella · 2 shared papers, 2025 · strength 0.41
  14. Gregory M. Springett · 7 shared papers, 2015–2017 · strength 0.40
  15. Ravi Shridhar · 7 shared papers, 2015–2017 · strength 0.40
  16. Ethan Bernard Ludmir · 2 shared papers, 2023–2026 · strength 0.35
  17. Dae Won Kim · 2 shared papers, 2023–2025 · strength 0.34
  18. José M. Pimiento · 2 shared papers, 2018–2025 · strength 0.28
  19. Tobin Joel Crill Strom · 5 shared papers, 2015–2017 · strength 0.28
  20. Richard D. Kim · 2 shared papers, 2015–2025 · strength 0.27
  21. Rachna T. Shroff · 1 shared paper, 2026 · strength 0.22
  22. Michael Frederick Bassetti · 1 shared paper, 2026 · strength 0.22
  23. Nina Niu Sanford · 1 shared paper, 2026 · strength 0.22
  24. Marsha Reyngold · 1 shared paper, 2026 · strength 0.22
  25. Karyn A. Goodman · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.